Safety data and side effects

SAFETY DATA

Short-term safety data suggests that transdermal testosterone therapy in doses that approximate physiological female levels:

• Does not impact breast cancer risk.
• Does not increase mammographic breast density.
• Has not been associated with increases in BP, blood glucose, HbA1c or lipid levels.

However, safety data is not available beyond 24 months of treatment.

Further studies are required to establish the long-term safety of testosterone for women, particularly the cardiometabolic and breast safety.

SIDE EFFECTS

For information on side effects, see review section.